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~ Coronary Ultrasound Thrombolysl m In Acute 
Myocardial Infarction: Results From the ACUTE 
Study 
U. Rosenschein ~ , I. Horlz ~ , E, Tenonbaum-Koren ~ , L. Thueson ~ ,
H.R. Andemen 1 . S, Lenlndo ~ , H,I. Miller ~ . R. Erbell". ~The TelAv/v 
So, smoky Medical Center, Tel Avlv, Israel; :Unlvorslttltskllnlkum Eases, 
Eases, Germany 
Backgroond: Clinical date suggest that therapeutic ultrasound selectively 
8blares thmmbl with wide margins of safety, The purpose of the ACUTE study 
la to evaluate the ~sfety nnd offloeoy of pomuf~noeus coronary ultrasound 
thrembolysls (CUT) as the primary repeduslon th0rnpy in acute anterior 
myocardial inf~mtlon (AMI) In n multleenter study, 
Mothed~: Patients (pie) wllh AMI nnd accIt=ded loft anterior descending 
~trtery w~m treated by CUT tieing a novel pemutsneeus thempeutto ultra- 
sound devtco, 
Re~o@: CUT was attempted in 3t conse0ulivo pls, Sontcalien (45 kHz, 
18W, 53 rain) Induced ~derlsl pstency in 29 (94% el the pls), (TIM101 flew 
hi 84%). end msld~sl stenosl~ of 54 :t,: 26%, Them worn no dissections, 
pedomtlons, ombolttatlon, spasm or "ne,roflow", Them were no adverse 
¢llnleel events d~ltlng CUT, Adjunct PTCA resulted in maid,let stenosia of t ? 
t, tB%, Steals were deployed in 7 pin (22%), Them wn~ no ndi~,lnet use of 
thrombolytte drugs, Reopm wnn administered in 1 pf (3",`"), In,hospital, I pt 
(3%) developed relnfarstlon, end 3 pts (t0",'.) had m~'urmnt ischemla with 
need for urgent target vessel revasculanzatian, Six pls (19%) I~ad CHF 
(NYHC :!:111), There were no claP, the, sffoke, blm~diflg or need tot vascular 
mpair, 
Conch~,~ton: CUT is potentially a nolo nnd effective devleo,solutien for 
mpeduslen therapy in the setting el AMI, 
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©Cr i t i ca l  Pathway for  Acute  ST Segment Elevation 
Myocardial Infarction: Evaluation of the Potential 
Impact In the TIMI 9 Regist ry  
C.P, Cannon, E,M, Antmsn, C,M, Gibson, S,D, Paul. E, Braunwnld. Etrlgham 
and Womon,~ Hospffal, ~oston, MA, USA 
Physicians ere under increasing pressure to reduce costs and maintain lllgh 
quality st care, cnttcal pathways may help accomplish this goal, We designed 
n critical pathway for acute MI which targets 100% use of appropriate medica- 
tions (I,o,, thrembolysts [or pnmnry angioplasty], nspidn, hepann, beta,block- 
era, ACE tnhlblters) and incorporates a strategy of early hospital discharge 
(day 4) tot low-ask patients. Cardiac catheterization is recommended only 
for ACC/AHA-recommoeded indications (recurrent ischemin, low ejection 
fraction, or other complication). We evaluated the potential impact of this 
critical pathway u.qin.q the TIMI 9 Registry database, where 840 consecutive 
patients with acute ST otovatton MI were enrolled at 20 hospitals in the U,S, 
and Canada. Thrombolysts was used in 503 (60%), pnmary angioplasty in 
77 (9%.) and no ropodusion therapy in 31%, Only 87% of pts. received as- 
pirin, Of those with documented LV dysfunction or congestive failure, 39% 
were treated with ACE inNbttera, indicating that use of a critical pathway 
targeting 100% use o1 th0so medications would improve care. To evaluate 
the potential economic impact of the critical pathway on low-risk patients, 
141 of 503 thrembolysis patients had no recurrent ischemia or MI, shock, 
CHF through discharge, Their mean length of stay was 8.2 :t 5.4 days, with 
88% staying in-hospital >than the target el 4 days, Of these uncomplicated 
patients, 110 had preserved LV function, yet 64% underwent catheterization 
and 33% underwent PTCA. For the 77 primary angioplasty patients, 38 had 
no complications, and their mean length of stay was 7,0 ~: 3.0 days, with 
90% staying ~-4 days, If the critical pathway were used for these low-risk 
patients (assuming costs of $t000/hospital day, $2000/cath, $3500/PTCA). 
over $500,000 could be saved for every 100 uncomplicated thrembolysis 
patients, and $350,000 for every 100 uncomplicated PTCA patients, 
Conclusions: 1) These findings from the TIMI 9 Registry demonstrate 
that significant opportunibes exist for improving the medical management 
of patients with acute MI, 2) Critical pathways may help reduce costs while 
preserving (or improving) quality of care. 
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~Long (;IT Genotype Can Be Identified by ECG 
Phenotype 
L,C. GIulI, L, Zheng, K,W, Timothy. J, Fox. D. Handrahen, A,J, Moss, 
W, Zemba, P,J. Schwartz. MH, Lehmena. M,T, Keeling, J,A, Towbin, 
G,M, Vincent, LOS Hospital, UniverMy st Utah, SLG LIT, USA 
B,Ickgmond: In a previous study we (Moss, el el) descnbed different ECG 
T,w~ve pnttores in the LOT1. ;~ nnd 3 genetypos, In this study, we assessed 
the dlsgnostig eensitivity/spe~ilieily of the Moss p~ttems and fonnu!~fed an 
enhanced criteria set based on now obsentafions, 
Mottmds: Two hundred 12.lead ECGs representing LOT1 (n = 55), LOT2 
(79), LOT3 (27), nnd unaffected (39) Qenotyped patients (all non,medicated) 
wore rend by blinded LOTS resoamhers, The ECGa were. classified as 
hP, vinQ a LOT1, LOT2, LQT3, unaffected, of an uncertain phenehq~e using 
Mess p~tlem; ST, T morphology, T w~ve amplitude and duration, The ECG's 
wnm also classified using Moss pattern plus new cnteria; ST length and 
slope; distinctiveness el T wave onseL/etfset, and T wave symmetry. In en 
expnnded set ot LQTt (n = 8B), LQT~ (10.3), and LOT3 (~) ~re's  we 
ovalusted age dependent pattsms. 
Re,~utt,~: 
Sens~ttvi~ Spe~tcay 
C~onotypo LQT1 LQI~ LQT3 NL LQTt LQT2 LOT3 NIL 
Mos~ O 22 030 056 O 92 eat o 93 097 078 
Now Cl'ttoria 0.87 O85 O 70 O.eS eat 094 099 097 
A new phenotype is described in LQT1 patients: short ST segment. 
asyn,motrical peaked T wave, and no clear T onset. (Sen Example) This new 
phonotype was oxpressed by 70% el LQTt children 0-5 yrs. 6% o! older 
LQTt children and adults, 0% of LOT2 children, 2% ot LOT2 adults, and 0% 
01 ell LOT3 patients, 
. . . . . . . . . . . . . . . . . . . . .  , . , , . . ,  
• , . ,H . . . . . . . . . . . . . . . . . . . . . . .  : .;;::::::::::::  . . . . .  ; : : : : - :  
Conclusion: Sensitivity was low in identifying LQTt and LOT2 using Moss 
patterns. Sensitivity increased significantly for LOT1 and LOT2 using new 
phenotypic cntona. In children -~ 6 yrs. ustng new cntena is essential for LQTt 
genotypo identification. 
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8~'~ Wavelet Analysis of Short-term Beat-to-Beat 
Variabi l i ty of Repolarization In LQTS Patients With 
SCN5A Sodium Channel MuteUon 
JP. Couderc, W. Zareba. A.J, Moss. Univ of Rochester. NY, USA 
Current techniques evaluating beat-to-beat variability of repolanzation rely on 
accurate determination of T-wave endpoints, This study proposes a method 
to detect a yen/short-term repotanzation variability in a standard 12.lead 
ECG using the wavelet transformation (WT) technique. 
Methods: Using wavelets from the second gaussian derivative, we filtered 
the repolarization segment to evaluate variability in 10 LOTS pts with SCN5A 
mutation (SCN5A+), 13 nonlinked family members (SCN5A).  and 28 un- 
related healthy subjects (N), From 10-second ECGs, segments beginning 
100 ms alter the R peek and ending 220 ms before the following R peak 
were analyzed. Two parameters quantified beat-to-beat changes of the re- 
polarization segment: the temporal vanability in time (TVT) and in amplitude 
(TVA). Mean value of TVT and TVA from the 12 leads were computed and 
compared to the mean value of the standard deviation of RT apex duration 
(SDRTm). a time-domain measure of variability. 
Results: Comparison of TVA, TVT, their combination, and SDRTm is 
shown in the Table (" p < 0.01, "" p < 0.00001 in reference to group N). 
N (n = 28) SCN5A- (n = 13) SCN5A+ (n = 10) 
SDRTm (ms) 8 ~,- 6 14 + 21 31 "~ 41" 
SDRTm -21 ms 4% 0% 40% 
TVA (%) 12 -,- 6 19 ± 9 29 4- 17"" 
TVT (ms) 4±2 5±3 15 :E 17" 
(1) TVA >24% 7% 23% 50% 
(2) TVT ~.2.1 ms 4% 14% 50% 
(1) or (2) 1 t % 30% 90% 
